Immunogenicity of BNT162b2 vaccine against the Alpha and Delta variants in immunocompromised patients with systemic inflammatory diseases

Article Rheumatology

Humoral and Cellular Immune Responses to SARS-CoV-2 Infection and Vaccination in Autoimmune Disease Patients With B Cell Depletion

David Simon et al.

Summary: The study found that B cell depletion completely blocks humoral response to SARS-CoV-2 vaccination, but not T cell response. Limited humoral immune responses were observed in patients with B cell depletion after SARS-CoV-2 infection.

ARTHRITIS & RHEUMATOLOGY (2022)

添加到收藏夹

Article Rheumatology

The effect of methotrexate and targeted immunosuppression on humoral and cellular immune responses to the COVID-19 vaccine BNT162b2: a cohort study

Satveer K. Mahil et al.

Summary: Patients receiving methotrexate may have impaired humoral immunity to a single dose of the BNT162b2 vaccine, but not those receiving targeted biologics. Cellular immune responses are preserved in all groups. Real-world pharmacovigilance studies are needed to determine the clinical effectiveness of these findings.

LANCET RHEUMATOLOGY (2021)

添加到收藏夹

Article Rheumatology

COVID-19 outcomes in patients with inflammatory rheumatic and musculoskeletal diseases treated with rituximab: a cohort study

Jerome Avouac et al.

Summary: Rituximab therapy is associated with more severe COVID-19 outcomes in patients with inflammatory rheumatic and musculoskeletal diseases, and should be prescribed with caution.

LANCET RHEUMATOLOGY (2021)

添加到收藏夹

Article Rheumatology

Severity of COVID-19 and survival in patients with rheumatic and inflammatory diseases: data from the French RMD COVID-19 cohort of 694 patients

Florence Aeschlimann et al.

Summary: In this French cohort study of RMD COVID-19 patients, older age, male gender, obesity, and hypertension were found to be associated with severe COVID-19, similar to the general population. Patients with iRMD on corticosteroids, but not methotrexate, tumor necrosis factor alpha, and interleukin-6 inhibitors, were more likely to develop severe COVID-19. Unlike common comorbidities, such as obesity, cardiovascular or lung diseases, the risk of death in patients with iRMD was not significantly increased.

ANNALS OF THE RHEUMATIC DISEASES (2021)

添加到收藏夹

Article Rheumatology

Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry

Anja Strangfeld et al.

Summary: Factors associated with COVID-19-related death in people with rheumatic diseases include age, sex, comorbidities, disease activity, and specific medications. Adequate disease control with disease-modifying anti-rheumatic drugs (DMARDs) without increasing glucocorticoid dosages is important, while caution may be required with certain medications such as rituximab and sulfasalazine.

ANNALS OF THE RHEUMATIC DISEASES (2021)

添加到收藏夹

Article Rheumatology

SARS-CoV-2 vaccination responses in untreated, conventionally treated and anticytokine-treated patients with immune-mediated inflammatory diseases

David Simon et al.

Summary: Immune response against SARS-CoV-2 is delayed and reduced in patients with immune-mediated inflammatory diseases, regardless of treatment.

ANNALS OF THE RHEUMATIC DISEASES (2021)

添加到收藏夹

Letter Rheumatology

Rituximab, but not other antirheumatic therapies, is associated with impaired serological response to SARS-CoV-2 vaccination in patients with rheumatic diseases

Robert Spiera et al.

ANNALS OF THE RHEUMATIC DISEASES (2021)

添加到收藏夹

Article Medicine, General & Internal

Safety and Cross-Variant Immunogenicity of a Three-dose COVID-19 mRNA Vaccine Regimen in Kidney Transplant Recipients

Filippo Massa et al.

Summary: A three-dose regimen of the BNT162b2 COVID-19 vaccine significantly improves anti-spike IgG levels, neutralizing antibodies, and cellular immune responses in kidney transplant recipients with a tolerable tolerability profile.

EBIOMEDICINE (2021)

添加到收藏夹

Meeting Abstract Rheumatology

IMPACT OF ABDOMINAL AORTIC CALCIFICATION AND SERUM CREATININE-TO-CYSTATIN C RATIO TO BONE FRAGILITY FRACTURE

I. Yoshii

ANNALS OF THE RHEUMATIC DISEASES (2021)

添加到收藏夹

Article Rheumatology

Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study

Victoria Furer et al.

Summary: Vaccination with mRNA BNT162b2 vaccine showed reduced immunogenicity in patients with AIIRD compared to the general population, with risk factors including older age and treatment with glucocorticoids, rituximab, mycophenolate mofetil (MMF), and abatacept. However, most patients maintained stable disease activity post-vaccination.

ANNALS OF THE RHEUMATIC DISEASES (2021)

添加到收藏夹

Article Rheumatology

Disease activity and humoral response in patients with inflammatory rheumatic diseases after two doses of the Pfizer mRNA vaccine against SARS-CoV-2

Yolanda Braun-Moscovici et al.

Summary: The vast majority of patients with inflammatory rheumatic diseases developed a significant humoral response following the administration of the second dose of the Pfizer mRNA vaccine against SARS-CoV-2 virus. Only minor side effects were reported and no apparent impact on IRD activity was noted.

ANNALS OF THE RHEUMATIC DISEASES (2021)

添加到收藏夹

Article Rheumatology

SARS-CoV-2 vaccination in rituximab-treated patients: B cells promote humoral immune responses in the presence of T-cell-mediated immunity

Daniel Mrak et al.

Summary: The study found that RTX-treated patients can develop SARS-CoV-2-specific antibodies after vaccination, but only if peripheral B cells at least partially repopulate. Additionally, more than half of the vaccinated patients developed SARS-CoV-2-specific T cells, which may provide protective effects regardless of humoral immune responses.

ANNALS OF THE RHEUMATIC DISEASES (2021)

添加到收藏夹

Letter Rheumatology

Methotrexate and glucocorticoids, but not anticytokine therapy, impair the immunogenicity of a single dose of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic inflammatory arthritis

Serena Bugatti et al.

ANNALS OF THE RHEUMATIC DISEASES (2021)

添加到收藏夹

Letter Oncology

Antibody response to SARS-CoV-2 vaccines in patients with hematologic malignancies

Lee M. Greenberger et al.

CANCER CELL (2021)

添加到收藏夹

Letter Medicine, General & Internal

Antibody Response After a Third Dose of the mRNA-1273 SARS-CoV-2 Vaccine in Kidney Transplant Recipients With Minimal Serologic Response to 2 Doses

Ilies Benotmane et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)

添加到收藏夹

Article Multidisciplinary Sciences

SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses

Jackson S. Turner et al.

Summary: SARS-CoV-2 mRNA vaccines induce a persistent germinal centre B cell response in humans, leading to the generation of robust humoral immunity, especially more significant in individuals previously infected with the virus.

NATURE (2021)

添加到收藏夹

Article Multidisciplinary Sciences

How the Delta variant achieves its ultrafast spread

Sara Reardon

NATURE (2021)

添加到收藏夹

Article Multidisciplinary Sciences

BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans

Ugur Sahin et al.

Summary: The BNT162b2 vaccine shows 95% efficacy in preventing COVID-19 by boosting neutralizing antibody titres and activating specific T cell responses. The vaccine-induced immune response is broad and stable, lasting for a prolonged period, providing good coverage against various SARS-CoV-2 variants.

NATURE (2021)

添加到收藏夹

Article Medicine, General & Internal